TENX

Tenax Therapeutics, Inc. (TENX) - Q1 2026 Filing Summary

Business Context and Reporting Period

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary therapies, specifically pulmonary hypertension. The company is advancing two primary product candidates: levosimendan (TNX-103) and imatinib. This Form 10-Q covers the quarterly period ended March 31, 2026. As of May 8, 2026, the company had 26,525,159 shares of Common Stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by 51% to $15.7 million, driven primarily by a 103% increase in Research and Development (R&D) expenses to $11.5 million. This increase reflects the expansion of the Phase 3 LEVEL trial and the commencement of the LEVEL-2 trial in December 2025.
• Capital Raise via Warrant Exercises: Financing activities generated $30.5 million in net cash, primarily from the exercise of warrants and pre-funded warrants ($30.5 million), compared to $23.6 million in the prior year which included proceeds from a new private placement offering.
• Share Count Expansion: Common shares outstanding increased from 9.3 million at December 31, 2025, to 24.3 million at March 31, 2026, due to significant exercises of pre-funded warrants and warrants.
• Working Capital: Working capital improved to $114.7 million from $97.1 million at the end of 2025.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes cash resources of $118.8 million (as of March 31, 2026), combined with $7.9 million received from warrant exercises subsequent to quarter-end, are sufficient to fund operations through at least the first quarter of 2028.
• Clinical Progress: The Phase 3 LEVEL study achieved target enrollment of 230 patients in March 2026. The LEVEL-2 trial commenced in December 2025 and is currently enrolling.
• Future Capital Needs: The company anticipates continuing to incur net losses for the foreseeable future. Future capital requirements depend on clinical trial progress, regulatory approvals, and potential commercialization costs.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional financing which may result in dilution, and the potential inability to secure necessary regulatory approvals. The company has no product revenue and relies on equity financing and warrant exercises.
• Subsequent Events: Thomas R. Staab, II was appointed Chief Financial Officer effective May 11, 2026. Between April and June 2026, the company received an additional $7.9 million from warrant exercises.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $118.8 million cash balance to fund operations through Q1 2028, considering the accelerated burn rate from two concurrent Phase 3 trials.
• Dilution Impact: Assess the impact of the significant increase in share count (from 9.3M to 24.3M shares) and the remaining 24.6 million pre-funded warrants and 10.5 million standard warrants outstanding.
• Clinical Milestones: Monitor the topline data announcement for the LEVEL trial, which triggers the expiration of certain August 2024 warrants.
• License Obligations: Review the Simdax license agreement with Orion Corporation for potential milestone payments (up to $45 million in commercialization milestones and $10 million upon FDA approval) that could impact future cash flow.
• Management Transition: Evaluate the integration of the new CFO and the impact of recent inducement option grants on future stock-based compensation expenses.